GLP-1 receptor modulators, initially developed for diabetes treatment in the 1970s, have emerged as leading drugs for substantial non-surgical weight loss, achieving 15-20% reductions in body weight. Expert Ben Locwin explains these agents mimic natural hormones influencing appetite regulation, offering a safer profile than traditional stimulant-based treatments. Despite their efficacy, side effects and variability in patient tolerance remain significant. The rising demand strains manufacturing capacity and raises ethical concerns regarding supply prioritization between diabetes and obesity patients, alongside risks posed by counterfeit products infiltrating unregulated markets.